Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPINEPHRINE vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors. Its effects include vasoconstriction (alpha-1), bronchodilation (beta-2), increased heart rate and contractility (beta-1), and relaxation of uterine and bladder smooth muscle.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Emergency treatment of anaphylactic reactions,Acute asthma exacerbation (subcutaneous injection),Cardiac arrest (ACLS protocol, intravenous or intraosseous),Treatment of hypotension associated with septic shock (off-label),Treatment of severe allergic reactions (epinephrine auto-injector),Local hemostatic agent (diluted solution, off-label)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
0.3-0.5 mg IM (auto-injector or syringe) every 5-15 minutes as needed for anaphylaxis; IV: 0.1-0.5 mg (1-10 mcg/min infusion) for hemodynamic support.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
1-2 minutes (intravenous); clinical effect termination primarily due to rapid uptake and metabolism, not elimination half-life.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Epinephrine is metabolized primarily by the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) in the liver, kidneys, and other tissues. The major metabolites are metanephrine, vanillylmandelic acid (VMA), and 3-methoxy-4-hydroxyphenylglycol (MOPEG).
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily hepatic metabolism via catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO); renal excretion of metabolites (inactive) and small fraction (<5%) unchanged.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Approximately 50% bound to albumin and alpha-1-acid glycoprotein.
~10-20% bound to plasma proteins (primarily albumin).
0.2-0.5 L/kg; reflects distribution into highly perfused tissues.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
IM: 80-100%, SC: 50-80%, oral: <2% (extensive first-pass metabolism), inhalation: 5-15%.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No dose adjustment required for renal impairment; use with caution in severe renal failure due to risk of hypertension and arrhythmias.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
No specific dose adjustment recommended for Child-Pugh class A, B, or C; monitor for exaggerated effects in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Anaphylaxis: 0.01 mg/kg IM (max 0.3 mg) every 5-15 minutes; IV: 0.01 mg/kg (0.1-1 mcg/min infusion) titrated to effect.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Use lower initial doses (e.g., 0.1-0.3 mg IM) and titrate cautiously due to increased sensitivity and higher risk of adverse effects (tachyarrhythmias, hypertension, myocardial ischemia).
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Epinephrine is not a substitute for immediate medical care in anaphylaxis. Patients should seek emergency medical attention immediately after use.
None
Use with caution in patients with cardiovascular disease (e.g., coronary artery disease, hypertension, arrhythmias), hyperthyroidism, diabetes, or pheochromocytoma.,May cause severe hypertension, myocardial ischemia, pulmonary edema, and cardiac arrhythmias.,Avoid extravasation; can cause local tissue necrosis due to alpha-mediated vasoconstriction.,May aggravate narrow-angle glaucoma.,Use with caution in elderly patients and those with cerebrovascular insufficiency.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to epinephrine or any component of the formulation.,Narrow-angle glaucoma (relative contraindication in emergency situations).,Use during second stage of labor may delay delivery.,Concurrent use with non-selective beta-blockers (e.g., propranolol) may cause severe hypertensive crisis.,Use in patients with hypovolemic shock (except as temporary measure in cardiac arrest).
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
No specific food interactions. Avoid alcohol as it may worsen hypotension. Caffeine and other sympathomimetics (e.g., weight loss supplements) can potentiate adverse effects.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
FDA Pregnancy Category C. Animal studies have shown adverse fetal effects, but no adequate human studies. Epinephrine causes reduced uterine blood flow and fetal hypoxia; risk of fetal harm if used during pregnancy, especially in the second and third trimesters. Avoid in first trimester unless necessary.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Epinephrine is excreted into breast milk in small amounts. M/P ratio unknown. Oral bioavailability is low, so systemic effects in infant are unlikely. Use with caution, monitor infant for signs of sympathetic stimulation.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No specific dose adjustment required for pregnancy. However, increased plasma volume and decreased sensitivity to catecholamines may require higher doses for hemodynamic effect. Use lowest effective dose and titrate to response. Monitor closely for adverse effects.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Administer epinephrine IM into the vastus lateralis for anaphylaxis; avoid gluteal and IV administration in non-arrest settings due to risk of arrhythmias. Intravenous infusion requires central line and continuous hemodynamic monitoring. Use with extreme caution in patients on non-selective beta-blockers (e.g., propranolol) due to unopposed alpha-mediated hypertension.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Seek emergency medical help immediately after using epinephrine auto-injector; symptoms may recur.,Do not delay use if anaphylaxis is suspected; early administration is crucial.,Inject into the outer middle thigh; can be done through clothing if necessary.,Massage injection site for 10 seconds after use to enhance absorption.,Always carry two auto-injectors; a second dose may be needed if symptoms persist.,Store at room temperature; protect from light and do not refrigerate.,Check expiration date regularly and replace as needed.,Train family and caregivers on proper usage.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPINEPHRINE vs ALDOMET, answered by our medical review team.
EPINEPHRINE is a Alpha/Beta Agonist that works by Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors. Its effects include vasoconstriction (alpha-1), bronchodilation (beta-2), increased heart rate and contractility (beta-1), and relaxation of uterine and bladder smooth muscle.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPINEPHRINE and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPINEPHRINE is: 0.3-0.5 mg IM (auto-injector or syringe) every 5-15 minutes as needed for anaphylaxis; IV: 0.1-0.5 mg (1-10 mcg/min infusion) for hemodynamic support.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPINEPHRINE and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPINEPHRINE is classified as Category A/B. FDA Pregnancy Category C. Animal studies have shown adverse fetal effects, but no adequate human studies. Epinephrine causes reduced uterine blood flow and fetal hypoxia; risk of f. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.